Sugi Predict

Sugi Predict / Compounds / SCHEMBL1998350

SCHEMBL1998350

SCHEMBL1998350

CC(=O)Oc1cc(F)cc(F)c1F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 2/20 0.46
▸ CYP4A11 Q02928 2/20 0.46
▸ CES2 O00748 4/20 0.45
▸ CES1 P23141 4/20 0.45
▸ TNFSF11 O14788 1/20 0.40
▸ KDM4E B2RXH2 5/20 0.39
▸ ALDH1A1 P00352 4/20 0.39
▸ TSHR P16473 3/20 0.39
▸ GAA P10253 2/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ CFD P00746 2/20 0.38
▸ HPGD P15428 3/20 0.37
▸ HSD17B10 Q99714 3/20 0.37
▸ USP2 O75604 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ GLA P06280 1/20 0.37
▸ HSP90AA1 P07900 1/20 0.37
▸ HSP90AB1 P08238 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ ALPG P10696 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24436697 0.82 CYP4F2 (0.42) CYP4F2CYP4A11TNFSF11KDM4EALDH1A1
SCHEMBL24436813 0.82 ERN1 (0.46) CYP4F2CYP4A11CES2CES1TNFSF11
SCHEMBL24436812 0.82 CYP4F2 (0.45) CYP4F2CYP4A11CES2CES1TNFSF11
SCHEMBL823844 0.82 CYP4F2 (0.47) CYP4F2CYP4A11CES2CES1TNFSF11
SCHEMBL31006941 0.82 CYP4F2 (0.47) CYP4F2CYP4A11CES2CES1TNFSF11
SCHEMBL15759388 0.80 CES2 (0.36) CES2CES1
SCHEMBL2001585 0.79 ALOX15 (0.41) CYP4F2CYP4A11CES2CES1KDM4E
SCHEMBL15763921 0.78 CES2 (0.44) CYP4F2CYP4A11CES2CES1RIPK1
SCHEMBL18341964 0.78 CYP4F2 (0.44) CYP4F2CYP4A11TNFSF11KDM4EALDH1A1
SCHEMBL10180794 0.77 CES2 (0.42) CES2CES1KDM4ETSHRGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10483466-B2 P-doping cross-linking of organic hole transporters SIEMENS AKTIENGESELLSCHAFT (DE) 2019-11-19 — — US claimed
EP-3114715-B1 P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS SIEMENS AG (DE) 2019-10-30 — — EP claimed
US-20180198069-A1 P-Doping Cross-Linking Of Organic Hole Transporters SIEMENS AKTIENGESELLSCHAFT (DE) 2018-07-12 — — US claimed
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 — — US claimed
US-10483466-B2 P-doping cross-linking of organic hole transporters SIEMENS AKTIENGESELLSCHAFT (DE) 2019-11-19 — — US disclosed
US-20180240975-A1 Bi-Nuclear Main Group Metal Phosphorescent Emitter SIEMENS AKTIENGESELLSCHAFT (DE) 2018-08-23 — — US disclosed
US-20180198069-A1 P-Doping Cross-Linking Of Organic Hole Transporters SIEMENS AKTIENGESELLSCHAFT (DE) 2018-07-12 — — US disclosed
EP-3114190-B1 BI-NUCLEAR MAIN GROUP METAL PHOSPHORESCENT EMITTER SIEMENS AG (DE) 2018-06-06 — — EP disclosed
CN-107667439-A Formulations comprising organic semiconductors and metal complexes 默克专利有限公司 2018-02-06 — — CN disclosed
CN-104168768-B The method of preparation Cgrp receptor antagonist 默沙东公司 2017-03-01 — — CN disclosed
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 — — US disclosed
CN-104168768-A Process for making cgrp receptor antagonists MERCK SHARP 2014-11-26 — — CN disclosed
US-20120219866-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2012-08-30 — — US disclosed
EP-2475041-A1 NON-AQUEOUS ELECTROLYTIC SOLUTION, AND NON-AQUEOUS ELECTROLYTE BATTERY COMPRISING SAME Mitsubishi Chemical Corporation (JP) 2012-07-11 — — EP disclosed
CN-102186921-A Fluorine-containing copolymer composition and process for production thereof ASAHI GLASS CO LTD 2011-09-14 — — CN disclosed
US-20110172336-A1 FLUOROCOPOLYMER COMPOSITION AND ITS PRODUCTION PROCESS ASAHI GLASS COMPANY, LIMITED (JP) 2011-07-14 — — US disclosed
EP-2338935-A1 FLUORINE-CONTAINING COPOLYMER COMPOSITION AND PROCESS FOR PRODUCTION THEREOF ASAHI GLASS COMPANY, LIMITED (JP) 2011-06-29 — — EP disclosed
US-20090162290-A1 METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF THERAPHARM GMBH 2009-06-25 — — US disclosed
US-20090162290-A1 METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF THERAPHARM GMBH 2009-06-25 — — US disclosed
WO-2007028639-A1 METHOD FOR THE SYNTHESIS OF PENTAPENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIO-CONJUGATES PREPARATION BY A COVALENT BINDING OF THEREOF THERAPHARM GMBH (CH) 2007-03-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180240975-A1 Bi-Nuclear Main Group Metal Phosphorescent Emitter FOXM1, NUCB2, L3MBTL3 CYP4F2 1525/4885CYP4A11 4416/4885CES2 4225/4885
US-20090162290-A1 METHOD FOR THE SYNTHESIS OF PENTA-PENDANT ENANTIOMER-PURE CHELATORS AND PROCESS FOR THERAPEUTICALLY ACTIVE BIOCONJUGATES PREPARATION BY A COVALENT BINDING THEREOF C5, C3AR1, SPR CYP4F2 359/4885CYP4A11 2866/4885CES2 1849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.